At Adamas, we are passionate about improving lives and making a meaningful difference for people affected by neurological diseases. We leverage our experience in drug discovery, development and commercialization to deliver innovative medicines that reduce the burden on patients, caregivers, and society, and build a foundation for growth.
GOCOVRI (amantadine) extended release capsules is the first and only FDA approved treatment for dyskinesia in Parkinson’s disease patients treated with levodopa therapy, with or without other medicines that increase the effects of dopamine in the brain. GOCOVRI is also clinically proven to treat dyskinesia while also reducing OFF time in PD.
See what it means to work with passionate, dedicated and spirited people who share a strong sense of purpose.
Our Investor Hub is designed to help you easily find the most important information about our company.